Core Viewpoint - A class action has been filed against Atara Biotherapeutics, Inc. for allegedly misleading investors regarding its drug candidate tabelecleucel, particularly concerning manufacturing issues and regulatory prospects [1][3]. Group 1: Class Action Details - The class period for the action is from May 20, 2024, to January 9, 2026 [3]. - The allegations include failure to disclose manufacturing issues and deficiencies in the ALLELE study, which impacted the likelihood of FDA approval for tabelecleucel [3]. - The complaint states that these undisclosed issues led to a significant negative impact on Atara's business and financial condition, making public statements materially false and misleading [3]. Group 2: Stock Price Impact - On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter (CRL) regarding the tabelecleucel BLA, stating that the trial was inadequate for evidence of effectiveness [4]. - Following this announcement, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share [4]. Group 3: Shareholder Actions - Shareholders may be eligible to participate in the class action and can submit their papers to serve as lead plaintiff by May 22, 2026 [5]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [5].

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. (ATRA) for securities fraud, affecting shareholders who acquired shares between May 20, 2024, and January 9, 2026, with a deadline for lead plaintiff motion set for May 22, 2026 [1]. Summary by Relevant Sections Company Background - Atara Biotherapeutics, Inc. is a biotechnology company focused on developing therapies for patients with serious diseases, including its Epstein-Barr treatment, tabelecleucel (EBVALLO) [4]. Events Leading to the Lawsuit - On January 16, 2025, Atara received a Complete Response Letter (CRL) from the FDA regarding its BLA for tabelecleucel, indicating that the application would not be approved in its current form, leading to a stock price drop of $5.33, or 40.5%, closing at $7.83 per share [4]. - On January 21, 2025, Atara announced a clinical hold on its active IND applications due to GMP compliance issues, resulting in a further stock price decline of $0.52, or 7.9%, to close at $6.05 per share [5]. - On January 12, 2026, Atara disclosed another CRL regarding the resubmitted tabelecleucel BLA, stating that the trial's design and conduct were inadequate for evidence of effectiveness, causing the stock price to fall by $7.79, or 56.99%, to close at $5.88 per share [6][7]. Allegations in the Lawsuit - The lawsuit alleges that Atara's management made materially false and misleading statements and failed to disclose significant adverse facts about the company's business and prospects, including: 1. Manufacturing issues and deficiencies in the ALLELE study that made FDA approval unlikely [7]. 2. Overstated regulatory prospects for tabelecleucel [7]. 3. Heightened risk of regulatory scrutiny due to manufacturing issues, jeopardizing ongoing clinical trials [7]. 4. Significant negative impacts on Atara's business and financial condition [7]. 5. Misleading positive statements regarding the company's operations and prospects [7].

Core Viewpoint - Atara Biotherapeutics, Inc. is facing a securities class action lawsuit due to allegations of misleading statements regarding the regulatory prospects of its product tabelecleucel, which may impact the company's financial condition and business operations [2]. Group 1: Allegations and Class Action Details - The class period for the lawsuit is from May 20, 2024, to January 9, 2026 [2]. - Allegations include that Atara failed to disclose manufacturing issues and deficiencies in the ALLELE study, which made FDA approval of tabelecleucel unlikely [2]. - The lawsuit claims that these undisclosed issues heightened regulatory scrutiny risks and jeopardized ongoing clinical trials, likely leading to significant negative impacts on Atara's business and financial condition [2]. Group 2: Shareholder Actions - Shareholders who purchased ATRA shares during the class period are encouraged to register for the class action, with a lead plaintiff appointment deadline set for May 22, 2026 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that inflated stock prices [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Atara Biotherapeutics, Inc. securities, alleging that the company made false and misleading statements regarding its regulatory prospects and manufacturing issues during the Class Period from May 20, 2024, to January 9, 2026 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Atara Biotherapeutics failed to disclose significant manufacturing issues and deficiencies in the ALLELE study, which made FDA approval of the tabelecleucel Biologics License Application unlikely [5]. - The lawsuit asserts that these undisclosed issues heightened regulatory scrutiny risks and jeopardized ongoing clinical trials, negatively impacting Atara's business and financial condition [5]. - Investors are encouraged to join the class action, with no out-of-pocket fees or costs due to a contingency fee arrangement [2][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4]. - Investors can join the class action by submitting a form or contacting the firm directly for more information [3][6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. and reminds investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [2][4]. Group 1: Allegations Against Atara Biotherapeutics - The complaint alleges that Atara and its executives violated federal securities laws by making false and/or misleading statements regarding manufacturing issues and deficiencies in the ALLELE study, which made FDA approval of the tabelecleucel BLA unlikely [4][9]. - It is claimed that the regulatory prospects of tabelecleucel were overstated, and the manufacturing issues subjected Atara to heightened regulatory scrutiny, jeopardizing ongoing clinical trials [4][9]. - The allegations suggest that these issues were likely to have a significant negative impact on Atara's business and financial condition, rendering the defendants' public statements materially false and/or misleading [4][9]. Group 2: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA regarding the EBVALLO™ (tabelecleucel) BLA, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share on January 12, 2026 [5][9]. Group 3: Legal Proceedings - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will direct and oversee the litigation on behalf of the putative class [6]. - Any member of the putative class may move the Court to serve as lead plaintiff or may choose to remain an absent class member without affecting their ability to share in any recovery [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Atara Biotherapeutics, Inc. securities during the specified Class Period, indicating potential legal issues related to the company's disclosures and regulatory prospects [1][5]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between May 20, 2024, and January 9, 2026, and a lead plaintiff must be appointed by May 22, 2026 [1][3]. - Investors who purchased Atara securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Allegations Against Atara Biotherapeutics - The lawsuit claims that Atara made false and misleading statements regarding manufacturing issues and regulatory prospects for its tabelecleucel Biologics License Application (BLA), which were overstated [5]. - It is alleged that these manufacturing issues heightened the risk of regulatory scrutiny and jeopardized ongoing clinical trials, likely leading to a significant negative impact on Atara's business and financial condition [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in representing investor interests effectively [4].

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. for allegedly issuing false and misleading statements regarding its business and regulatory prospects, particularly concerning the tabelecleucel Biologics License Application [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Atara securities between May 20, 2024, and January 9, 2026, with a deadline of May 22, 2026, for investors to apply as lead plaintiffs [2]. - Allegations include that manufacturing issues and deficiencies in the ALLELE study made FDA approval for tabelecleucel unlikely, overstating its regulatory prospects [3]. Group 2: Impact on Atara - The alleged manufacturing issues have heightened the risk of regulatory scrutiny and jeopardized ongoing clinical trials, likely leading to a significant negative impact on Atara's business and financial condition [3]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the claims are encouraged to contact the law firm for more details, with no cost or obligation [4]. Group 4: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents investors in securities litigation and has a nationwide practice [5].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Atara Biotherapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and undisclosed manufacturing issues that may have affected the company's regulatory prospects and financial condition [1][3]. Group 1: Allegations - The complaint alleges that during the class period from May 20, 2024, to January 9, 2026, Atara Biotherapeutics issued materially false and/or misleading statements [3]. - Specific allegations include that manufacturing issues and deficiencies in the ALLELE study made FDA approval of the tabelecleucel BLA unlikely [3]. - The company is accused of overstating the regulatory prospects of tabelecleucel, which subjected it to increased regulatory scrutiny and jeopardized ongoing clinical trials [3]. Group 2: Impact on Business - The aforementioned issues are likely to have a significant negative impact on Atara's business and financial condition [3]. - The public statements made by the defendants were materially false and/or misleading at all relevant times, potentially leading to investor losses [3]. Group 3: Next Steps for Shareholders - Shareholders who purchased shares of ATRA during the specified timeframe are encouraged to register for the class action by May 22, 2026, to participate in potential recovery [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed manufacturing issues affecting the company's product approval process [2][5]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Atara between May 20, 2024, and January 9, 2026, to discuss their legal options [1]. - A federal securities class action has been filed against Atara, with a deadline of May 22, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Atara and its executives made false statements regarding the regulatory prospects of the tabelecleucel BLA, which were overstated due to manufacturing issues [5]. Group 2: Impact of FDA Response - On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter for the EBVALLO™ BLA, indicating that the application could not be approved in its current form due to inadequacies in the ALLELE trial [6]. - Following the FDA's announcement, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

Core Viewpoint - A class action has been filed against Atara Biotherapeutics, Inc. for allegedly misleading investors regarding its drug candidate tabelecleucel, particularly concerning its regulatory prospects and manufacturing issues [1][2]. Group 1: Company Overview - Atara Biotherapeutics, Inc. focuses on developing therapies for solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the U.K. [1] - The company's lead product candidate is tabelecleucel, a T-cell immunotherapy for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease [1]. Group 2: Allegations and Impact - The complaint alleges that during the class period, Atara failed to disclose significant manufacturing issues and deficiencies in the ALLELE study, which made FDA approval of tabelecleucel unlikely [2]. - It is claimed that these undisclosed issues heightened regulatory scrutiny and jeopardized ongoing clinical trials, likely leading to a significant negative impact on Atara's business and financial condition [2]. - Following the announcement of a Complete Response Letter from the FDA on January 12, 2026, Atara's stock price dropped by $7.79 per share, or 56.99%, closing at $5.88 per share [3]. Group 3: Legal Proceedings - Shareholders interested in participating in the class action must submit their papers by May 22, 2026, to serve as lead plaintiff [4]. - The lead plaintiff will represent other class members in directing the litigation, although participation is not required for recovery [4].